Organization | Pivotal S.L.

Pivotal S.L. Report issue

For profit Phase 2 Phase 3 Phase 4

Founded: Madrid Spain (2001)

Organization Overview

First Clinical Trial

2008

NCT00721747

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Pivotal S.L.

Active Ingredients

Drugs in Phase 4 Trials (1)

adalimumab (humira) (1 trial)

Drugs in Phase 3 Trials (4)

fludeoxyglucose f-18 (1 trial)

ibuprofen (motrin) (1 trial)

pentixafor (1 trial)

sodium chloride (1 trial)

Drugs in Phase 2 Trials (21)

aflibercept (zaltrap) (1 trial)

avelumab (bavencio) (1 trial)

carboplatin (paraplatin) (1 trial)

cetuximab (erbitux) (1 trial)

cyclophosphamide (cytoxan) (2 trials)

docetaxel (taxotere) (2 trials)

doxorubicin (Doxil) (2 trials)

everolimus (zortress) (1 trial)

fluorouracil (efudex) (4 trials)

gemcitabine (gemzar) (1 trial)

irinotecan (Camptosar) (2 trials)

leucovorin (4 trials)

oxaliplatin (eloxatin) (2 trials)

paclitaxel (taxol) (2 trials)

panitumumab (vectibix) (3 trials)

pbf-680 (1 trial)

prednisone (meticorten) (1 trial)

rituximab (rituxan) (1 trial)

sapanisertib (1 trial)

sunitinib (sutent) (1 trial)

vincristine (oncovin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Asthma (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Colorectal Neoplasms (Phase 2)

Crohn Disease (Phase 4)

Head and Neck Neoplasms (Phase 2)

Kidney Neoplasms (Phase 2)

Lymphoma (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Pain, Postoperative (Phase 3)

Prostatic Neoplasms (Phase 2)

Rectal Neoplasms (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 15
# of Trial APIs: 26